Gilead Sciences, Inc.
NEWS
Gilead has announced they are pulling cancer drug Zydelig (idelalisib) off the market for certain types of cancer after failing to complete follow-up clinical trials to confirm efficacy and safety.
Gilead Sciences reported that about $250 million of counterfeit versions of its HIV drugs, Biktarvy and Descovy, were sold to pharmacies over two years.
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
Unlike antibody-drug conjugates (ADCs) that focus on antigens, PDCs are able to target the tumor microenvironment that has universal features across solid tumors.
Pardes is funneling the funds into financing the next stage of clinical trials and commercial production of its lead oral antiviral drug, PBI-0451, for the treatment and prevention of SARS-CoV-2 infections.
Companies large and small have increased the prices of their drugs so far this week. The drug price increases when the market is seeing high inflation.
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between.
Ten studies are halted completely. Oral formulations of the drug will continue. Gilead stated that it is confident about the future of the drug’s potential and is working to resolve the vial quality problem.
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.
JOBS
IN THE PRESS